Perfluorohexyloctane
As of the edition of 20 October 2026, Perfluorohexyloctane is a small molecule: marketed, first approved in 2023 (US); US protection ends in 2028.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Miebo
- First approved
- 18 May 2023 (US)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- Bausch Health
- Registered trials
- 12, 2 stopped early
- Disease areas
- Eye
US protection
US protection ends in 2028.
The last listed US exclusivity ends in 2028. The application that gives this date is held by Bausch Health.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 5 | 3 | 0 | 2 |
| Phase 4 | 6 | 4 | 2 | 0 |
| All trials | 12 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bausch Health | Originator and Lead sponsor of trials | 2020 to now |